Pahor M, Manto A, Pedone C, Carosella L, Guralnik J M, Carbonin P
Department of Internal Medicine and Geriatrics, Catholic University, Rome, Italy.
J Clin Epidemiol. 1996 Aug;49(8):921-8. doi: 10.1016/0895-4356(96)00056-x.
The association of age with risk for severe adverse drug reactions (SADRs) was studied in 2371 and 862 hospitalized patients taking nifedipine and verapamil, respectively. Nifedipine caused hypotension (n = 22), tachycardia (n = 3), and acute renal failure (n = 1) (total SADR rate, 1.1%, 26/2371). Verapamil caused hypotension (n = 3), bradycardia (n = 9), and atrioventricular blocks (n = 2) (total SADR rate, 1.6%, 14/862). The mean age of patients with and without SADRs was for nifedipine 77.1 +/- 1.7 and 71.8 +/- 0.8 years, respectively (p < 0.05), and for verapamil 73.4 +/- 2.9 and 73.1 +/- 0.4 years, respectively. Sex, length of stay, comorbidity, polypharmacy, intake of slow-release preparations, daily dosage, and new intake of calcium antagonists were examined as potential confounders of the age-SADR association. After adjusting for potential confounders, age was significantly and independently associated with SADRs caused by nifedipine, but not with SADRs caused by verapamil (OR = 1.69, 95% CI = 1.05-2.72 and OR = 1.06, 95% CI = 0.63-1.68 for 10-year increase, respectively). Although nifedipine and verapamil did not have significantly different rates of SADRs, an age-related gradient was found only for nifedipine.
分别在2371例服用硝苯地平的住院患者和862例服用维拉帕米的住院患者中研究了年龄与严重药物不良反应(SADR)风险的相关性。硝苯地平导致低血压(n = 22)、心动过速(n = 3)和急性肾衰竭(n = 1)(SADR总发生率为1.1%,26/2371)。维拉帕米导致低血压(n = 3)、心动过缓(n = 9)和房室传导阻滞(n = 2)(SADR总发生率为1.6%,14/862)。发生和未发生SADR的患者平均年龄,硝苯地平组分别为77.1±1.7岁和71.8±0.8岁(p<0.05),维拉帕米组分别为73.4±2.9岁和73.1±0.4岁。对性别、住院时间、合并症、联合用药、缓释制剂摄入、每日剂量以及钙拮抗剂新摄入量作为年龄-SADR关联的潜在混杂因素进行了检查。在对潜在混杂因素进行校正后,年龄与硝苯地平引起的SADR显著且独立相关,但与维拉帕米引起的SADR无关(每增加10岁,OR分别为1.69,95%CI = 1.05 - 2.72和OR = 1.06,95%CI = 0.63 - 1.68)。虽然硝苯地平和维拉帕米的SADR发生率没有显著差异,但仅在硝苯地平中发现了与年龄相关的梯度。